Similar articles for PMID: 22684105

Year	Number of Results
1990	1
1995	1
1996	1
2001	2
2002	1
2003	1
2006	1
2007	4
2008	1
2009	1
2010	7
2011	9
2012	8
2013	10
2014	6
2015	13
2016	9
2017	8
2018	6
2019	7
2020	7
2021	11
2022	3
2024	0

1

Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.

Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J. Bellucci R, et al. J Clin Invest. 2012 Jul;122(7):2369-83. doi: 10.1172/JCI58457. Epub 2012 Jun 11. J Clin Invest. 2012. PMID: 22684105 Free PMC article.

2

Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.

Freeman AJ, Vervoort SJ, Ramsbottom KM, Kelly MJ, Michie J, Pijpers L, Johnstone RW, Kearney CJ, Oliaro J. Freeman AJ, et al. Cell Rep. 2019 Sep 10;28(11):2784-2794.e5. doi: 10.1016/j.celrep.2019.08.017. Cell Rep. 2019. PMID: 31509742 Free article.

3

Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C. Lupardus PJ, et al. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8025-30. doi: 10.1073/pnas.1401180111. Epub 2014 May 19. Proc Natl Acad Sci U S A. 2014. PMID: 24843152 Free PMC article.

4

JAK kinases overexpression promotes in vitro cell transformation.

Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. Knoops L, et al. Oncogene. 2008 Mar 6;27(11):1511-9. doi: 10.1038/sj.onc.1210800. Epub 2007 Sep 17. Oncogene. 2008. PMID: 17873904

5

Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.

Bommarito D, Martin A, Forcade E, Nastke MD, Ritz J, Bellucci R. Bommarito D, et al. Cancer Immunol Immunother. 2016 Mar;65(3):355-66. doi: 10.1007/s00262-016-1804-y. Epub 2016 Feb 16. Cancer Immunol Immunother. 2016. PMID: 26883876 Free PMC article.

6

Loss of JAK1 Drives Innate Immune Deficiency.

Witalisz-Siepracka A, Klein K, Prinz D, Leidenfrost N, Schabbauer G, Dohnal A, Sexl V. Witalisz-Siepracka A, et al. Front Immunol. 2019 Jan 8;9:3108. doi: 10.3389/fimmu.2018.03108. eCollection 2018. Front Immunol. 2019. PMID: 30671064 Free PMC article.

7

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.

Curran SA, Shyer JA, St Angelo ET, Talbot LR, Sharma S, Chung DJ, Heller G, Hsu KC, Betts BC, Young JW. Curran SA, et al. Cancer Immunol Res. 2017 Jan;5(1):52-60. doi: 10.1158/2326-6066.CIR-16-0233. Epub 2016 Dec 6. Cancer Immunol Res. 2017. PMID: 27923824 Free PMC article.

8

Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.

Malerich JP, Lam JS, Hart B, Fine RM, Klebansky B, Tanga MJ, D'Andrea A. Malerich JP, et al. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7454-7. doi: 10.1016/j.bmcl.2010.10.026. Epub 2010 Oct 13. Bioorg Med Chem Lett. 2010. PMID: 21106455

9

Janus kinase 2--a novel negative regulator of estrogen receptor α function.

Gupta N, Grebhardt S, Mayer D. Gupta N, et al. Cell Signal. 2012 Jan;24(1):151-61. doi: 10.1016/j.cellsig.2011.08.016. Epub 2011 Sep 1. Cell Signal. 2012. PMID: 21907792

10

Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.

Xu LJ, Ma Q, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR, Shan YX. Xu LJ, et al. Mol Med Rep. 2018 Jun;17(6):8111-8120. doi: 10.3892/mmr.2018.8905. Epub 2018 Apr 20. Mol Med Rep. 2018. PMID: 29693186 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year